Skip to main content

Table 3 Diagonal linear discriminant analysis of NSCLC cell lines

From: Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors

    Predicted sensitivity to EGFR TKI
  Cell Line Experimental Sensitivity to EGFR TKI (erlotinib) Prediction based on analysis of mutational status alone (Exons 18–21) Genomic signature/DLDA   
     10-genes 50-genes 180-genes
Training A549 No √*
  UKY-29 No  
  H1650 Yes
  PC-9 Yes
  H3255 Yes
Validation H358 Yes  
  H460 No
  H1975 No    
  K562 No
  A431 Yes  
   % Correct 80% 80% 90% 90%
  1. Predictions of EGFR TKI sensitivity are denoted for ten cell lines used in training/validation. Column 2 demonstrates experimental sensitivity to an EGFR TKI, erlotinib (Table 1). Column 3 demonstrates prediction of sensitivity using mutational status of EGFR. Columns 4–6 denote prediction of sensitivity of the cell lines using the 10, 50, and 180 gene signatures in DLDA. √: denotes correct prediction based on experimental sensitivity to EGFR TKI. *: Leave-a-group-out cross-validation incorrectly predicts 3 of 8 replicates of this cell line.